Abstract
Sullivan SD, Buxton M, Andersson LF, et al. J Allergy Clin Immunol . 2003;112:1229–1236 These investigators analyzed cost-effectiveness of a commonly prescribed inhaled corticosteroid from the perspectives of both direct and indirect costs. Patients aged 5 to 66 years from 32 countries were enrolled in the Inhaled Steroid as Regular Therapy in Early Asthma (START) study. Patients were eligible if they were diagnosed with asthma within 2 years of randomization and lacked significant comorbidity. START was a randomized, 3-year controlled trial of budesonide versus usual asthma therapy in early-onset asthma among …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
